Home » Topics » Dermatologic, BioWorld Science

Dermatologic, BioWorld Science
RSS

Phase II trial of Twin for acne achieved primary and secondary efficacy endpoints

July 21, 2017

European approval for Kyntheum for moderate to severe plaque psoriasis

July 20, 2017

FDA designates StrataGraft a regenerative medicine advanced therapy

July 19, 2017

Abeona receives guidance on phase III trial of EB-101 for epidermolysis bullosa

July 19, 2017

NICE final guidance recommends Humira, Enbrel and Stelara for plaque psoriasis in children

July 18, 2017

Novartis has 5-year data for Cosentyx in plaque psoriasis

July 18, 2017

FDA approves Tremfya for moderate to severe plaque psoriasis

July 14, 2017

FDA awards orphan drug status to Principia Biopharma's PRN-1008

July 12, 2017

FDA clinical hold on Concert Pharmaceuticals' trial of CTP-543 lifted

July 11, 2017

Novan presents new data on SB-204 in adolescents

July 10, 2017

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 2, 2026.
Deep brain stimulation from the shallows: tomorrow’s BCI technology?
BioWorld
Deep brain stimulation (DBS) through implanted electrodes has enabled fundamentally new ways of treating certain disorders. More than 100,000 severely ill...
CINP 2026: organoids reveal autism and addiction mechanisms
BioWorld Science
At the 2026 World Congress of Neuropsychopharmacology (CINP), held in Glasgow June 26-29, 2026, researchers from Japan’s National Center of Neurology and...
Ontrack Therapeutics divulges compounds for neurodegenerative diseases
BioWorld Science
Ontrack Therapeutics Ltd. has reported new heterotricyclic compounds potentially useful for the treatment of neurodegenerative diseases.
Reunion Neuroscience reports new 5-HT2A partial agonists and/or 5-HT2B antagonists
BioWorld Science
Reunion Neuroscience Inc. has identified new 5-HT2A receptor partial agonists and/or 5-HT2B receptor antagonists potentially useful for the treatment of...